AU Patent

AU2014345570B2 — Glucagon-GLP-1-GIP triple agonist compounds

Assigned to Zealand Pharma AS · Expires 2019-01-24 · 7y expired

What this patent protects

The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.

USPTO Abstract

The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.

Drugs covered by this patent

dasiglucagon-hydrochloride (DASIGLUCAGON HYDROCHLORIDE)

Patent Metadata

Patent number: AU2014345570B2
Jurisdiction: AU
Classification: —
Expires: 2019-01-24
Drug substance claim: No
Drug product claim: No
Assignee: Zealand Pharma AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.